AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11753809 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus placebo
Number of subjects: 263
Study 9289303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever wheezers
Number of subjects: 161
Study 9289303 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezers in the last 12 months
Number of subjects: 161
Study 9289303 — intervention group
Group type: COMPARATOR
Intervention: Exercise challenge test
Number of subjects: 161
Study 8388357 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin (2,500 IU)
Number of subjects: 1290
Study 8388357 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin (3,500 IU)
Number of subjects: 1290
Study 8388357 — intervention group
Group type: COMPARATOR
Intervention: UF heparin (2 x 5,000 IU)
Number of subjects: 1290
Study 2879969 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 0
Study 2879969 — intervention group
Group type: COMPARATOR
Intervention: Complex carbohydrate diet
Number of subjects: 0
Study 30192786 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (case management and behavioral activation)
Number of subjects: 626
Study 30192786 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 626
Study 27658215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led onsite mentoring program
Number of subjects: 108
Study 24612686 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D displays
Number of subjects: 15
Study 24612686 — intervention group
Group type: COMPARATOR
Intervention: 2D displays
Number of subjects: 15
Study 24024838 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 198
Study 24024838 — intervention group
Group type: COMPARATOR
Intervention: 1.25 g testosterone gel daily
Number of subjects: 198
Study 24024838 — intervention group
Group type: COMPARATOR
Intervention: 2.5 g testosterone gel daily
Number of subjects: 198
Study 24024838 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g testosterone gel daily
Number of subjects: 198
Study 24024838 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g testosterone gel daily
Number of subjects: 198
Study 24024838 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel with anastrozole
Number of subjects: 198
Study 21540740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 90
Study 21540740 — intervention group
Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 90
Study 21540740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (ACT and AR)
Number of subjects: 90
Study 18438830 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 218
Study 18438830 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 180 mg
Number of subjects: 218
Study 18438830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 16284225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowers
Number of subjects: 30
Study 16284225 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 30
Study 14519177 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selegiline plus nicotine patch
Number of subjects: 109
Study 14519177 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nicotine patch
Number of subjects: 109
Study 10714415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 mcg b.d.
Number of subjects: 30
Study 10714415 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast 20 mg b.d.
Number of subjects: 30
Study 9185029 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg once daily for 8 weeks
Number of subjects: 204
Study 9185029 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 204
Study 7968325 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extradural morphine group (n = 35)
Number of subjects: 105
Study 7968325 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal extradural morphine group (n = 35)
Number of subjects: 105
Study 7968325 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 105
Study 3569631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 54
Study 3569631 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) (2 to 3 injections/day, self blood glucose monitoring)
Number of subjects: 54
Study 30354579 — intervention group
Group type: EXPERIMENTAL
Intervention: MINT-TLC intervention plus motivational interviewing
Number of subjects: 373
Study 30354579 — intervention group
Group type: COMPARATOR
Intervention: HE control group
Number of subjects: 373
Study 27433887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for childhood anxiety disorders
Number of subjects: 66
Study 24793909 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvers (⩾30% baseline to 2‐month reduction on the Insomnia Severity Index [ISI])
Number of subjects: 367
Study 24793909 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvers
Number of subjects: 367
Study 22763669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol condition (BAC <0.05%) with low THC (1.8% THC)
Number of subjects: 80
Study 22763669 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol condition (BAC >0.05%) with low THC (1.8% THC)
Number of subjects: 80
Study 22763669 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol condition (BAC >0.05%) with high THC (3% THC)
Number of subjects: 80
Study 22763669 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette (0% THC) with alcohol (not specified if low or high)
Number of subjects: 80
Study 16045185 — intervention group
Group type: EXPERIMENTAL
Intervention: JWiTS regimen for Wilms tumor
Number of subjects: 0
Study 16045185 — intervention group
Group type: EXPERIMENTAL
Intervention: New regimen for MRTK
Number of subjects: 0
Study 12453257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 25
Study 12453257 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using oral contraceptives
Number of subjects: 25
Study 12453257 — intervention group
Group type: COMPARATOR
Intervention: Control group (male students)
Number of subjects: 25
Study 12453257 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 25
Study 12453257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile threshold (TT)
Number of subjects: 25
Study 9843458 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million U)
Number of subjects: 61
Study 9843458 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (up to 100 mg)
Number of subjects: 61
Study 9843458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thrombolytic therapy)
Number of subjects: 61
Study 8593716 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/cm2 of sphinganine in ethanol (50 microliters of a 1.6% solution)
Number of subjects: 0
Study 8593716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% sphingosine in ethanol-petrolatum ointment
Number of subjects: 0
Study 8593716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% sphinganine in ethanol
Number of subjects: 0
Study 2527675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms thrice daily for two weeks
Number of subjects: 15
Study 2527675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2527675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 15
Study 326688 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-isopropyl-4-phenyl-7-methyl-2 (1H) quinazolone
Number of subjects: 20
Study 326688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31169568 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg 4 times a day)
Number of subjects: 16
Study 31169568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg 4 times a day)
Number of subjects: 16
Study 31169568 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 29797155 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR up-training/Theta down-training (SMR⇑Theta⇓)
Number of subjects: 30
Study 29797155 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta up-training/SMR down-training (Theta⇑SMR⇓)
Number of subjects: 30
Study 26306603 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink
Number of subjects: 90
Study 26306603 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched drink
Number of subjects: 90
Study 26306603 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 90
Study 26306603 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Carbohydrate-rich drink, Protein-enriched drink, Tap water)
Number of subjects: 90
Study 25525519 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of Entonox
Number of subjects: 100
Study 25525519 — intervention group
Group type: COMPARATOR
Intervention: Intermittent use of Entonox
Number of subjects: 100
Study 22706930 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Spaced Education (SE) programme
Number of subjects: 0
Study 22706930 — intervention group
Group type: COMPARATOR
Intervention: Online slide show followed by a quiz (SQ)
Number of subjects: 0
Study 22706930 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Spaced Education (SE) programme among surgical interns
Number of subjects: 0
Study 22706930 — intervention group
Group type: COMPARATOR
Intervention: Online slide show followed by a quiz (SQ) among surgical interns
Number of subjects: 0
Study 19775203 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib (250 mg)
Number of subjects: 59
Study 19775203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 18308908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for case managers to manage substance use disorders
Number of subjects: 232
Study 18308908 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 232
Study 18308908 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 232
Study 16240429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical tourniquet (number 1 polyglactin suture tied around the cervix)
Number of subjects: 28
Study 16240429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 28
Study 12142655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 814
Study 12142655 — intervention group
Group type: COMPARATOR
Intervention: Standard closure methods
Number of subjects: 814
Study 10201462 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus omeprazole
Number of subjects: 1151
Study 10201462 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 1151
Study 10201462 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 1151
Study 8522724 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEX (dexamethasone)
Number of subjects: 68
Study 8522724 — intervention group
Group type: COMPARATOR
Intervention: P (saline placebo)
Number of subjects: 68
Study 2141590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingelheim M inhalator
Number of subjects: 60
Study 2141590 — intervention group
Group type: EXPERIMENTAL
Intervention: Berodual Inhaletten
Number of subjects: 60
Study 41548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (30 mg)
Number of subjects: 0
Study 41548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipotassium chlorazepate (15 mg)
Number of subjects: 0
Study 41548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31421295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism present in patients with hypertensive intracerebral hemorrhage (54 patients, 23.4%)
Number of subjects: 462
Study 31421295 — intervention group
Group type: COMPARATOR
Intervention: No hypothyroidism in matched controls (33 patients, 14.3%)
Number of subjects: 462
Study 31023750 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training, twice a week for 12 weeks
Number of subjects: 44
Study 31023750 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 44
Study 31023750 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 44
Study 27839705 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wavelength LLLT (628 nm)
Number of subjects: 16
Study 27839705 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared wavelength LLLT (828 nm)
Number of subjects: 16
Study 27839705 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat treatment
Number of subjects: 16
Study 27839705 — intervention group
Group type: COMPARATOR
Intervention: No heat-light (control) treatment
Number of subjects: 16
Study 26058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and vorinostat
Number of subjects: 16
Study 23261048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-valent oral rotavirus vaccine (3 doses)
Number of subjects: 0
Study 23261048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21323475 — intervention group
Group type: EXPERIMENTAL
Intervention: NASAL-18 technique
Number of subjects: 48
Study 21323475 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (control)
Number of subjects: 48
Study 21323475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 21323475 — intervention group
Group type: EXPERIMENTAL
Intervention: NASAL-18 group
Number of subjects: 48
Study 19185772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitality Diet (VD) - low-sodium DASH-type diet including 6 servings of 100 g cooked lean red meat per week
Number of subjects: 111
Study 19185772 — intervention group
Group type: COMPARATOR
Intervention: Reference Healthy Diet (RHD) - higher acid load diet based on general dietary guidelines
Number of subjects: 111
Study 17098874 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 12
Study 17098874 — intervention group
Group type: COMPARATOR
Intervention: Guided progressive relaxation (Control)
Number of subjects: 12
Study 15200448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (prophylactic repair of AV graft stenosis)
Number of subjects: 64
Study 15200448 — intervention group
Group type: COMPARATOR
Intervention: Observation group (repair only in the event of thrombosis)
Number of subjects: 64
Study 11276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture model methodology for handling non‐ignorable drop‐outs in longitudinal studies
Number of subjects: 0
Study 11276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture model for non‐ignorable drop‐outs
Number of subjects: 0
Study 11276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear model for the conditional mean of the outcome vector given time of drop out
Number of subjects: 0
Study 11276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameterization of the general linear mixture model
Number of subjects: 0
Study 9042119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg first dose, 0.3 mg/kg for the next 2 mornings)
Number of subjects: 61
Study 9042119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume, identical appearance)
Number of subjects: 61
Study 9042119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 61
Study 9042119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 8159441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (250 mcg/kg i.v. slow push)
Number of subjects: 6
Study 8159441 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of ketamine
Number of subjects: 6
Study 8159441 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose injections of ketamine
Number of subjects: 6
Study 3124047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium (1.5 mg/kg per day)
Number of subjects: 113
Study 3124047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 31900231 — intervention group
Group type: EXPERIMENTAL
Intervention: Your Heart Forecast (YHF)
Number of subjects: 0
Study 31900231 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 28815341 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa once weekly (QW)
Number of subjects: 116
Study 28815341 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 2 weeks (Q2W)
Number of subjects: 116
Study 28815341 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 26686309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 4000 IU
Number of subjects: 164
Study 26686309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 6000 IU
Number of subjects: 164
Study 26686309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 2×4000 IU
Number of subjects: 164
Study 25659956 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV1
Number of subjects: 288
Study 25659956 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV2
Number of subjects: 288
Study 25659956 — intervention group
Group type: COMPARATOR
Intervention: DET
Number of subjects: 288
Study 23073362 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of attachment-related avoidance
Number of subjects: 65
Study 23073362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate levels of attachment-related avoidance
Number of subjects: 65
Study 23073362 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-related anxiety
Number of subjects: 65
Study 23073362 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment dimensions
Number of subjects: 65
Study 20135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine‐prilocaine mixture
Number of subjects: 46
Study 20135832 — intervention group
Group type: COMPARATOR
Intervention: No topical anesthesia (Control)
Number of subjects: 46
Study 18204342 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily for 8 weeks
Number of subjects: 20
Study 18204342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18204342 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily
Number of subjects: 20
Study 16616973 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 253
Study 16616973 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 253
Study 15030297 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)
Number of subjects: 0
Study 15030297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone inhibition and combination therapy (ACEI/ARB)
Number of subjects: 0
Study 15030297 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies targeting post-translational endothelial and mesangial messengers
Number of subjects: 0
Study 10686575 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8884309 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate potassium (200mg in 10ml saline solution)
Number of subjects: 30
Study 8884309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10ml saline solution)
Number of subjects: 30
Study 2071559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 126
Study 2071559 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (250 mg/day)
Number of subjects: 126
Study 6851419 — intervention group
Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 8
Study 6851419 — intervention group
Group type: COMPARATOR
Intervention: Mental tasks
Number of subjects: 8
Study 6851419 — intervention group
Group type: COMPARATOR
Intervention: Mueller and Valsalva manoeuvres
Number of subjects: 8
Study 6851419 — intervention group
Group type: EXPERIMENTAL
Intervention: Coughing during expiration
Number of subjects: 8
Study 6851419 — intervention group
Group type: COMPARATOR
Intervention: Chemical stimulation (inhalation of citric acid)
Number of subjects: 8
Study 30887844 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus Panitumumab
Number of subjects: 19
Study 30887844 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus Bevacizumab
Number of subjects: 19
Study 30887844 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus anti-EGFR combinations
Number of subjects: 19
Study 30887844 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 19
Study 30054587 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic bag with standard care
Number of subjects: 300
Study 30054587 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable thermal nest (PTN) with standard care
Number of subjects: 300
Study 30054587 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 300
Study 25385307 — intervention group
Group type: EXPERIMENTAL
Intervention: Colder water (5, 7, 10°C)
Number of subjects: 113
Study 25385307 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric‐cooled apparatus
Number of subjects: 113
Study 25385307 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 12 to 14 years
Number of subjects: 113
Study 25385307 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 10 to 11 years
Number of subjects: 113
Study 25385307 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 113
Study 25404438 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube insertion
Number of subjects: 148
Study 25404438 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 148
Study 22561099 — intervention group
Group type: EXPERIMENTAL
Intervention: SES (n = 20)
Number of subjects: 38
Study 22561099 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 18)
Number of subjects: 38
Study 22561099 — intervention group
Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 38
Study 19890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 12